Protalix BioTherapeutics (PLX) Times Interest Earned (2013 - 2025)
Protalix BioTherapeutics' quarterly Times Interest Earned came in at -$690.83 in Q1 2025, down 5448.29% year-on-year from $12.92 in Q1 2024, and down 492.9% quarter-over-quarter from $175.83 in Q4 2024.
Protalix BioTherapeutics has reported Times Interest Earned for 13 years, with the latest figure at -$690.83 in Q1 2025.
- For the quarter ending Q1 2025, Times Interest Earned fell 5448.29% year-over-year to -$690.83; the trailing twelve-month figure through Dec 2025 stood at -$196.33 (down 5463.2% YoY), and the FY2024 full-year result was $3.69, up 12.13% from the prior year.
- Times Interest Earned for Q1 2025 stood at -$690.83, down from $175.83 in the prior quarter.
- The five-year high for Times Interest Earned was $175.83 in Q4 2024, with the low at -$690.83 in Q1 2025.
- Average Times Interest Earned over 5 years is -$31.54, with a median of -$4.1 recorded in 2023.
- Year-over-year, Times Interest Earned surged 2523.72% in 2024 and plunged 5448.29% in 2025.
- Tracing PLX's Times Interest Earned over 5 years: stood at -$6.28 in 2021, then soared by 283.51% to $11.53 in 2022, then sank by 162.91% to -$7.25 in 2023, then surged by 2523.72% to $175.83 in 2024, then plunged by 492.9% to -$690.83 in 2025.
- The last three Times Interest Earned figures came in at -$690.83 (Q1 2025), $175.83 (Q4 2024), and $15.35 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -690.83 |
| Dec 31, 2024 | 175.83 |
| Sep 30, 2024 | 15.35 |
| Jun 30, 2024 | -6.40 |
| Mar 31, 2024 | -12.45 |
| Dec 31, 2023 | -7.25 |
| Sep 30, 2023 | -4.10 |
| Jun 30, 2023 | 15.65 |
| Mar 31, 2023 | -3.79 |
| Dec 31, 2022 | 11.53 |
| Sep 30, 2022 | -4.89 |
| Jun 30, 2022 | -8.87 |
| Mar 31, 2022 | -3.03 |
| Dec 31, 2021 | -6.28 |
| Sep 30, 2021 | -0.78 |
| Jun 30, 2021 | -4.16 |
| Mar 31, 2021 | -1.72 |
| Dec 31, 2020 | 1.13 |
| Sep 30, 2020 | -1.31 |
| Jun 30, 2020 | -1.15 |
| Mar 31, 2020 | 1.45 |
| Dec 31, 2019 | 1.05 |
| Sep 30, 2019 | -0.75 |
| Jun 30, 2019 | -3.06 |
| Mar 31, 2019 | -2.88 |
| Dec 31, 2018 | -1.97 |
| Sep 30, 2018 | -2.07 |
| Jun 30, 2018 | -3.76 |
| Mar 31, 2018 | -2.32 |
| Dec 31, 2017 | -10.46 |
| Sep 30, 2017 | -2.11 |
| Jun 30, 2017 | -3.55 |
| Mar 31, 2017 | -3.05 |
| Dec 31, 2016 | -5.90 |
| Sep 30, 2016 | -7.31 |
| Jun 30, 2016 | -11.02 |
| Mar 31, 2016 | -8.70 |
| Dec 31, 2015 | -8.28 |
| Sep 30, 2015 | -4.86 |
| Jun 30, 2015 | -8.70 |
| Mar 31, 2015 | -4.65 |
| Mar 31, 2014 | -7.07 |
| Mar 31, 2013 | -316.36 |